|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
ImClone Systems (2008)
Prevail Therapeutics (2020)
Loxo_Oncology_(2019)
|
|
gptkbp:awards
|
Fortune 500
Best Places to Work
World's_Most_Admired_Companies
Top_Employers_USA
|
|
gptkbp:CEO
|
gptkb:David_A._Ricks
|
|
gptkbp:clinicalTrials
|
gptkb:COVID-19
Osteoarthritis
Heart Disease
Alzheimer's Disease
Breast Cancer
|
|
gptkbp:employees
|
35,000 (2020)
|
|
gptkbp:foundedIn
|
1876
|
|
gptkbp:founder
|
gptkb:Eli_Lilly
|
|
gptkbp:has
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:headquarters
|
gptkb:Lilly_Corporate_Center
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
LLY
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:isHeadquarteredIn
|
gptkb:Indianapolis,_Indiana
|
|
gptkbp:market
|
$150 billion (2021)
|
|
gptkbp:partnerships
|
gptkb:Boehringer_Ingelheim
gptkb:Pfizer
gptkb:Amgen
|
|
gptkbp:patentCitation
|
gptkb:Insulin_Glargine
Cymbalta
Trulicity
Taltz
Verzenio
|
|
gptkbp:philanthropy
|
gptkb:Lilly_Endowment
gptkb:Lilly_Foundation
|
|
gptkbp:products
|
Insulin
Antidepressants
Cancer medications
|
|
gptkbp:researchFocus
|
Immunology
Neuroscience
Oncology
Diabetes
|
|
gptkbp:revenue
|
$28.5 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:LLY
|
|
gptkbp:subsidiary
|
gptkb:Lilly_France
gptkb:Lilly_Japan
gptkb:Lilly_Research_Laboratories
gptkb:Lilly_China
gptkb:Lilly_Canada
Lilly USA, LLC
|
|
gptkbp:sustainabilityInitiatives
|
Diversity and Inclusion
Environmental Stewardship
Access_to_Medicines
Global_Health
|
|
gptkbp:tradedOn
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:website
|
www.lilly.com
|